Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of ramoplanin to treat diseases associated with the use of antibiotics

a technology of ramoplanin and ramoplanin, which is applied in the direction of antibacterial agents, drug compositions, peptide/protein ingredients, etc., can solve the problems of clindamycin patients being highly susceptible to cdad, allergic reactions, intolerances, and so as to inhibit the relapse of antibiotic-associated diarrhea

Inactive Publication Date: 2007-01-18
NANOTHERAPEUTICS INC
View PDF12 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] In another related aspect, the invention features a method of inhibiting relapse of antibiotic-associated diarrhea in a patient by administering ramoplanin in an amount and for a duration effective to inhibit relapse of antibiotic-associated diarrhea in the patient.
[0013] The invention also features a method for preventing sporulation of C. difficile in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to prevent sporulation of C. difficile.

Problems solved by technology

Antibiotic-associated diarrheal diseases are caused by enterotoxin producing strains of Clostridium difficile, Staphylococcus aureus and Clostridium perfringens, and represent a major economic burden to the healthcare system, that is conservatively estimated at $3-6 billion per year in excess hospital costs in the U.S. alone.
Patients treated with clindamycin appear to be highly susceptible to CDAD presumably due to its prolonged effects on the indigenous anaerobic bowel flora.
While both vancomycin and metronidazole are generally very well tolerated and effective, allergies, intolerances, and side effects to both agents do occur.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ramoplanin to treat diseases associated with the use of antibiotics
  • Use of ramoplanin to treat diseases associated with the use of antibiotics
  • Use of ramoplanin to treat diseases associated with the use of antibiotics

Examples

Experimental program
Comparison scheme
Effect test

example 1

Efficacy of Ramoplanin in the Hamster Model of C. difficile Associated Colitis

[0068] To evaluate the in vivo efficacy of ramoplanin in the treatment of C. difficile-associated colitis, ramoplanin was tested in a hamster model of clindamycin (CL)-induced colitis in comparison with both vancomycin and metronidazole. Animals were treated with a single subcutaneous (s.c.) injection of 100 mg / kg clindamycin, and after 24 hours received oral ramoplanin or vancomycyin at 50 mg / kg / day for 5 days. Animals were observed daily for the presence or absence of diarrhea. Necropsies were performed on some animals that died during the experiment, and cecal contents were assayed for C. difficile toxin A. Hamsters were monitored for 20 days, and the cumulative mortality during this period was recorded (FIG. 1). Clindamycin alone rapidly induced a fatal enterocolitis with 100% mortality within 4 days. Autopsy revealed hemorrhagic ceca and watery stools. C. difficile toxin A was always detected in thes...

example 2

Oral Administration of Ramoplanin to Humans

[0072] As is described in detail below, single oral doses (up to 1000 mg) and multiple oral doses (200, 400, or 800 mg BID for 10 days) of ramoplanin have been administered to healthy male volunteers. Both bioassay and HPLC-based assays to assess the absorption, distribution, metabolism, and excretion were utilized in these studies. Ramoplanin was not detected in serum / plasma or urine by either method, indicating that very little, if any, is absorbed. Treatment with oral ramoplanin at all doses was efficacious in reducing the Gram-positive colony counts in feces to undetectable levels during the 10-day regimen. Ramoplanin was not effective against Gram-negative flora

[0073] Single Dose Study in Healthy Male Volunteers

[0074] The absorption, tolerability, and recovery of ramoplanin following single dose oral administration were investigated in male volunteers. Ramoplanin was administered as an aqueous solution at a dose of 100, 200, 500, or...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
resistanceaaaaaaaaaa
densityaaaaaaaaaa
Login to View More

Abstract

The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the presence of a bacterium such as enterotoxin producing strains of C. difficile, C. perfringens, or S. aureus.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 10 / 454,998, filed Jun. 5, 2003, which claims the benefit of U.S. Provisional Application No. 60 / 385,902, filed on Jun. 6, 2002, and U.S. Provisional Application No. 60 / 469,803, filed May 12, 2003. The entire teachings of the above applications are incorporated herein by reference.FIELD OF THE INVENTION [0002] This invention relates to the treatment of diseases associated with the use of antibiotics, such as colitis, pseudomembranous colitis, and antibiotic associated diarrhea. BACKGROUND OF THE INVENTION [0003] Antibiotic-associated diarrheal diseases are caused by enterotoxin producing strains of Clostridium difficile, Staphylococcus aureus and Clostridium perfringens, and represent a major economic burden to the healthcare system, that is conservatively estimated at $3-6 billion per year in excess hospital costs in the U.S. alone. [0004]Clostridium difficile associated di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/14A61K9/64A61K31/573A61K31/58A61K38/16A61K45/06
CPCA61K31/573A61K31/58A61K38/16A61K45/06A61K2300/00A61P1/12A61P31/04
Inventor JABES, DANIELALEACH, TIMOTHY S.LABAUDINIERE, RICHARD F.RAUSCHER, STEVEN M.
Owner NANOTHERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com